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Introduction
Solid cancers have several common characteristics that Hanahan & Weinberg named as the hallmarks of cancer [1] . Angiogenesis is an essential hallmark of cancer because tumor cells need oxygen and nutrients delivered by the vascular system [2] . In fact, tumor growth and metastasis are angiogenesis dependent processes, and microvascular endothelial cells recruited by tumors have become an important target in cancer therapy [1] [2] [3] .
Drug discovery efforts have identified several potential therapeutic targets in endothelial cells and selective inhibitors capable of slowing tumor growth or producing tumor regression by blocking angiogenesis in in vivo tumor models [4] . However, the currently available therapies have limited success in patients, due to complex mechanisms of resistance of the tumor cells [5, 6] . One approach to overcoming these problems is to use combinations of drugs with different modes of action that may lead to enhanced antitumor and antiangiogenic effects without injuring the host [5] [6] [7] . The combined use of two drugs may sometimes produce enhanced, unchanged or diminished effects in comparison with their individual effects. These three different types of behaviour of the interacting drugs are called synergy, additive/indifferent and antagonistic effects [8] .
Our research group is devoted to the screening, identification and characterization of new modulators of angiogenesis. In the last years we have identified a number of natural compounds as new inhibitors of angiogenesis [see for instance [9] [10] [11] [12] [13] [14] . We have also claimed for the need of combinatorial approaches to manage angiogenesis [5] .
Epigallocatechin-3-gallate (EGCG) is an abundant polyphenol in green tea leaves with a number of biological activities, including antiangiogenesis [5] , anticarcinogenesis [16] [17] [18] , antimetastasis [19] , as well as cancer chemoprevention, among others [20] . Furthermore, our group has previously shown that EGCG is a potent antiinflammatory compound [21, 22] targeting histidine decarboxylase [23] [24] [25] .
In the present work, we analyze paired combinations of EGCG with other 10 bioactive compounds (see Table 1 ), some described by our research group as potent antiangiogenic compounds, and others currently used in clinical therapy [11] [12] [13] [14] [26] [27] [28] [29] [30] [31] [32] .
Material and methods

Materials
Metformin, leflunomide, TNP-470, sunitinib malate, kahweol, cholecalciferol (vitamin 
Cell culture
The immortalized human microvascular endothelial cell (HMEC) line was kindly supplied by Dr. Arjan W. Griffioen (Maastrich University, The Netherlands). This immortalized cell line has been previously characterized [33] . HMEC cells were grown in RPMI 1640 medium supplemented with glutamine (2mM), penicillin (50 IU/mL), streptomycin (0.05 mg/mL), and amphotericin (1.25 mg/L) supplemented with 10% fetal bovine serum, and 10% human serum. Human breast cancer carcinoma MDA-MB-231 cells were purchased from ATCC and maintained in RPMI 1640 supplemented with glutamine (2mM), penicillin (50 IU/mL), streptomycin (0.05 mg/mL), and amphotericin (1.25 mg/L) supplemented with 10% fetal bovine serum. Cell cultures were maintained at 37°C under a humidified 5% CO 2 atmosphere. From these experiments, the effect of paired combinations was evaluated with two different approaches: determination of combination indexes and sensitization factors (see sections 2.4 and 2.5).
MTT cell growth assay
Combination index (CI)
The so-called combination index (CI) is defined as:
C a an C b are the concentrations of compounds A and B used together to achieve a fixed effect. IC a and IC b are the concentrations of A and B, respectively required individually to achieve the same effect [8] . Here, we have used as a fixed effect that corresponding to IC 50 . A CI value of less than, equal to, and more than one, indicates synergy, additivity and antagonism, respectively, between these two compounds.
Sensitization factors
The sensitization factors indicate he degree of sensitization induced by EGCG on the effects of the 10 selected compounds on cell survival. They were calculated as the ratio of IC 50 (control cells)/ IC 50 (EGCG treated cells). Figure 2 and Table 2 show the effects of exposure schedules of EGCG on HMEC endothelial cells treated with each of the 10 selected test compounds ( Figure 3 and Table 3 show the effects of exposure schedules of EGCG on MDA-MB231 tumor cells treated with each of the 10 selected test compounds (Table 1) .
Results
Studies of cell growth and survival with single compounds
Sensitivity of HMEC to the selected compounds in the presence of EGCG
Changes in the IC 50 (Table 3) 
Discussion
In the last years the convenience of combinatory approaches yielding synergistic antitumoral and antiangiogenic effects are more and more claimed [5, 7] . EGCG is a natural compound with a wide array of biological activities. In fact, EGCG has been shown to have antitumor, antiangiogenic and antiinflammatory effects [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . This makes EGCG a potentially interesting candidate for screening studies searching for synergistic combinations.
Some previous studies have analyzed the effects of combinations of EGCG with several compounds. For instance, EGCG nanoparticles enhance the cancer chemosensitization potential of cisplatin [34] . Combinations of EGCG with IL-1R antagonist are effective downregulating IL-1-induced tumorigenic factors in U-2 OS human osteosarcoma cells [35] . Another combination with positive inhibitory effects is that of EGCG combined with capecitabine, which inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts [36] . Some combinations of EGCG have been reported to induce antagonistic effects. Thus, EGCG has been shown to inhibit IGF-I-stimulated lung cancer angiogenesis and nicotine-induced migration and invasion of non-small cell lung cancer cells [37, 38] . On the other hand, there are some few studies reporting synergistic interactions of EGCG with other compounds. EGCG has been reported to sensitize human prostate cancer cells to TRAIL-mediated apoptosis, both treatments synergistically inhibiting angiogenesis and metastasis associated biomarkers [39] .
Another study demonstrated that curcumin synergizes with EGCG when administered in a sequential fashion overcoming stromal protection of chronic lymphocytic leukemia B cells [40] . EGCG and Vorinostat exhibit synergistic anticancer effects against human cholangiocarcinoma cells [41] .
For the screening of potential synergistic interactions of EGCG combined with other compounds, we decided to use as a first approach the analysis of the effects of endothelial and tumor cell survival as determined by the MTT assay, a simple, rapid and inexpensive procedure widely used for screening purposes. The list of 10 selected compounds for screening of their paired combinations with EGCG (Table 1 ) includes 4 natural compounds previously described as antiangionenic agents by our group, namely, 4-methylumbelliferone [14] , dimethyl fumarate [11] , hydroxytyrosol [13] and kahweol [12] . The list includes other two antiangiogenic compounds (leflunomide and TNP-470) and four antitumoral compounds (metformin, Paclitaxel, sunitinib and vitamin D 3 ).
Paclitaxel and sunitinib are currently used in the clinic. Paclitaxel is currently used for the treatment of several kinds of cancer, including breast, ovarian and lung cancer [26] .
Sunitinib has been described as an antitumoral agent by its potent inhibition of the phosphorylation of tyrosin kinases and was approved in 2006 by FDA as an antiangiogenic therapy [27] . TNP-470 is an antiangiogenic compound with a very strong inhibitory effect on endothelial cell proliferation [28] . Leflunomide is an immunomodulatory drug inhibiting mitochondrial enzyme dihydrorotate dehydrogenase, which plays a key role in the de novo synthesis of the pyrimidine ribonucleotide uridine monophosphate (rUMP) [29] . Metformin is a compound used in diabetes treatment and as antitumoral because it interferes with the mTOR pathway [30, 31] . The beneficial role of the vitamin D3 in suppressing inflammation with subsequent colon cancer prevention is well documented [32] . 
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